- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01440062
Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)
July 28, 2021 updated by: Jan-Markus Dörr, Charite University, Berlin, Germany
Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis
Examination of efficacy, safety and tolerability of vitamin D3 in the treatment of Multiple Sclerosis (MS).
Study Overview
Status
Terminated
Conditions
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité - Universitätsmedizin Berlin
-
Berlin, Germany
- Neurologische Praxis
-
Berlin, Germany
- Neurologisches Facharztzentrum
-
Halle, Germany
- Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Potsdam, Germany
- Sankt Josefs Krankenhaus Potsdam Neurologie
-
-
Brandenburg
-
Teupitz, Brandenburg, Germany
- Kliniken für Neurologie Teupitz/Lübben, Asklepios Fachkliniken Brandenburg GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent
- Age between 18 and 65 at randomization
- Relapsing-remitting MS according to the revised McDonald-Criteria (2005)
- EDSS ≤ 6,0
- Stable immunomodulatory treatment for at least 3 months
- Sufficient birth control (Pearl-Index <1) and negative pregnancy test at screening/randomization
Exclusion Criteria:
- Any other MS-course than RRMS
- Treatment with high dose vitamin D within 6 months prior to randomization
- Patients who have received over the last three months prior to randomization, an immunomodulatory therapy with the exception of IFN-β1b (Betaferon ®)
- Any condition that could interfere with MRI or other study related investigation
- Intolerability to Gd-DTPA
- Hypersensitivity to the drug Colecalciferol
- Patients with sarcoidosis
- Presence or history of nephrolithiasis
- Pseudohypoparathyroidism
Clinically relevant dysfunction of liver, bone narrow or kidney defined by the following laboratory values:
- HB <8.5 g / dl
- WBC <2.5 / nl
- platelet count <100/nl
- Creatinine clearance by Cockcroft-Gault formula: Cl <110ml/min (male) and Cl <95ml/min (female)
- AST / ALT> 3.5 times higher than the upper reference value
- bilirubin> 2.0 mg / dl
- hypercalcaemia> 2.7 mmol / l
- calcium / creatinine ratio in urine> 1
- Treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates
- Pregnancy or lactation period
- Participation in any clinical study within 3 months before or at any time during study
- Any medical, psychiatric or other condition that could interfere with the patient's ability to understand and give the informed consent, to comply with the protocol or to finish the study any ruling commitment or placement in an institution
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Verum (high dose)
verum arm receiving high dose Vitamin D oil
|
oil: 20000 IU/g tablet: 400 IU/g every second day
|
Experimental: Verum (low dose)
low dose arm receiving neutral oil and low dose of Vitamin D
|
neutral oil and a low dose of vitamin D
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy parameters
Time Frame: 1 day
|
efficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety & tolerability parameters
Time Frame: 1 day
|
Routine laboratory, vital signs, physical examination, ECG, AE reporting, Quality of Life
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Jan-Markus Dörr, Dr., Charité
- Principal Investigator: Jan-Markus Dörr, Dr., Charite-NeuroCure
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Backer-Koduah P, Infante-Duarte C, Ivaldi F, Uccelli A, Bellmann-Strobl J, Wernecke KD, Sy M, Demetriou M, Dorr J, Paul F, Ulrich Brandt A. Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. Ann Clin Transl Neurol. 2020 Sep;7(9):1628-1641. doi: 10.1002/acn3.51148. Epub 2020 Aug 23.
- Dorr J, Backer-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, Brockmeier B, Hoffmann O, Anvari K, Wuerfel J, Piper SK, Bellmann-Strobl J, Brandt AU, Paul F. High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Mult Scler J Exp Transl Clin. 2020 Jan 24;6(1):2055217320903474. doi: 10.1177/2055217320903474. eCollection 2020 Jan-Mar.
- Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials. 2012 Feb 8;13:15. doi: 10.1186/1745-6215-13-15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
September 19, 2011
First Submitted That Met QC Criteria
September 23, 2011
First Posted (Estimate)
September 26, 2011
Study Record Updates
Last Update Posted (Actual)
July 29, 2021
Last Update Submitted That Met QC Criteria
July 28, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Micronutrients
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
Other Study ID Numbers
- EVIDIMS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Verum arm receiving Vitamin D oil
-
Charite University, Berlin, GermanyNeuroCure Clinical Research Center, Charite, BerlinTerminatedMOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (MOVING)Multiple SclerosisGermany
-
University College DublinSt Vincent's University Hospital, Ireland; University of Dublin, Trinity CollegeCompletedMultiple Sclerosis | Clinically Isolated SyndromeIreland
-
Brigham and Women's HospitalNational Cancer Institute (NCI)Active, not recruitingBenign Breast DiseaseUnited States
-
Indiana UniversityWithdrawnArthritis, Rheumatoid | Vitamin D DeficiencyUnited States
-
Barts & The London NHS TrustNational Health Service, United KingdomCompletedRespiratory Tract Infections | InfluenzaUnited Kingdom
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
University College DublinDepartment of Agriculture Food and the MarineCompletedVitamin D Deficiency | Aging WellIreland
-
Brigham and Women's HospitalCompletedHeart FailureUnited States
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedCognitive DeclineUnited States
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH)Active, not recruitingDepression | Depressive Symptoms | MoodUnited States